Tarek Mostafa

Scopus Publications

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial
Khadija A.M. Glal, Sahar M. El-Haggar, Sherief M. Abdel-Salam, Tarek M. Mostafa
Scientific Reports, 2026
Efficacy and safety of baclofen in the prophylaxis of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a randomized controlled trial
Aya Gamal Moussa, Sahar Mohammed El-Haggar, Tamer Mosaad El-Mahdy, Tarek Mohamed Mostafa
BMC Surgery, 2026
Ketotifen for Preventing Oxaliplatin-Induced Neuropathy in Stage III Colorectal Cancer: a Randomized Controlled Trial
Salma S. Wahby, Tarek M. Mostafa, Mohamed A. Alm El-Din, Eman I. Elberri
Journal of Gastrointestinal Cancer, 2026
Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
Bassant M. Mahboub, Ayman F. Refaie, Sahar M. El-Haggar, Yasser M. Hafez, Tarek M. Mostafa
Diabetology and Metabolic Syndrome, 2026
Background Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding CKD progression with exploring supposed mechanistic pathways in clinical settings. Methods In this 12-month randomized controlled trial, 120 moderate CKD patients were randomized into three groups: metformin 1000 mg/day ( n = 40) or empagliflozin 10 mg/day ( n = 40), both added orally to standard treatment, or control who continued standard of care ( n = 40). The primary outcome was changes in estimated glomerular filtration rate (eGFR). Secondary analyses assessed percent changes of urinary albumin-to-creatinine ratio (uACR), transforming growth factor-β1 (TGF-β1), kidney injury molecule (KIM)-1, and beclin-1 (an autophagy biomarker). Other metabolic and safety issues were also assessed. Results 118 patients completed the study with comparable baseline data. Metformin and empagliflozin halted the decline in eGFR at study end with adjusted mean difference ± SE: 8.91 ± 1.92 ( p ˂0.001) and 5.1 ± 1.89 ( p = 0.03), respectively, compared to control group. Metformin preserved its effect in diabetics and non-diabetics, with superiority than empagliflozin in non-diabetics. uACR was lowered by metformin and empagliflozin than control. Both of them tended to halt the deterioration of intermediates with %relative change of -28.8% (95% CI, -44.4 to -9, p = 0.003) and 179.3% (95% CI, 32.2 to 490, p = 0.003), for metformin versus control in TGF-β1 and beclin-1 levels, respectively. Empagliflozin reduced KIM-1 compared to control [-29% (95% CI, -49.3 to -0.5, p = 0.045)]. Study treatments showed benefits on lipid profile without changing urate levels significantly compared to the control arm. No significant changes were found between metformin and empagliflozin. Adverse effects were comparable across groups with tolerable increased urination frequency by empagliflozin. Conclusion 12-month metformin therapy demonstrated renoprotective effects comparable to empagliflozin, with a greater effect observed among non-diabetics as an exploratory insight. Metformin’s renal actions were linked to antifibrotic and favorable autophagy effects while, empagliflozin preserved mainly tubular injury. Safety issues were generally comparable. Clinicaltrials.Gov identifier NCT05373680, registered on 13/5/2022 “retrospectively”. Graphical abstract
Probiotic Supplementation as an Adjuvant Therapy in Pediatric Drug-Resistant Epilepsy: A Double-Blind Placebo-Controlled Trial
Amira R. Rashdan, Sahar M. El‐Haggar, Ahmed Mustafa Kishk, Tarek M. Mostafa
Pharmacotherapy, 2026
Background Drug‐resistant epilepsy (DRE) is increasingly linked to neuroinflammatory mechanisms driven by gut dysbiosis. These mechanisms compromise blood–brain barrier integrity, enhance seizure susceptibility, and modulate immune pathways. These insights underscore the therapeutic potential of microbiota‐targeted interventions in epilepsy. Aim The study aimed at assessing the effectiveness of probiotics as an adjunctive therapy to enhance drug sensitivity and clinical outcomes in children with DRE. Methods This randomized, double‐blind, placebo‐controlled trial enrolled 60 pediatric patients with DRE who were assigned to either the control group ( n = 30), which received a standard antiepileptic regimen (valproic acid, oxcarbazepine, and levetiracetam at the maximum tolerated doses) plus a daily placebo capsule, or the probiotic group ( n = 30), which received the same antiepileptic regimen plus a daily probiotic ( Lactobacillus acidophilus ) supplement. The study duration was 6 months. Assessments of clinical and biochemical outcomes were conducted at baseline and 6 months after intervention. Primary end points included seizure frequency and change in quality of life as measured by the quality of life in childhood epilepsy (QOLCE‐55) questionnaire. Secondary end points included the change in the serum levels of high‐mobility group box 1 protein (HMGB1), interleukin‐1β (IL‐1β), homocysteine (Hcy), and NLR family pyrin domain‐containing 3 (NLRP3). Results After 6 months and relative to the control group, the probiotic ( Lactobacillus acidophilus ) group experienced a significant decline in seizure frequency ( p = 0.04) and a significant improvement in the QOLCE‐55 total score ( p < 0.0001). Additionally, the probiotic group exhibited significant decreases in the serum levels of HMGB1 ( p = 0.0005), NLRP3 ( p = 0.002), Hcy ( p = 0.001), and IL‐1β ( p = 0.05) compared with the control group. Conclusion Lactobacillus acidophilus supplementation appears to enhance the effectiveness of conventional antiepileptic drugs, reduce systemic inflammation, improve quality of life, and reduce seizure frequency in children with DRE. However, further validation is necessary. Clinicaltrials.gov Registration Number NCT05539287.
A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole—A Single-Institution Randomized Placebo-Controlled Trial
Ahmed E. S. Besheir, Sahar M. El-Hagar, Hesham A. Tawfik, Tarek M. Mostafa
Current Oncology, 2026
Background: The five-year survival rate of patients with ovarian cancer remains less than 50%, secondary to chemotherapy resistance. Purpose: This study aims to evaluate the effects of itraconazole as a supplementary treatment with paclitaxel and carboplatin on malignancy response and in preventing the initial development of chemoresistance in chemotherapy-naïve patients with advanced ovarian epithelial cancer. Method: This randomized placebo-controlled double-blind study involved 60 chemotherapy-naïve patients with advanced epithelial ovarian malignancy who were randomized into two arms; the placebo and itraconazole groups. The placebo group received six chemotherapy cycles and four inactive capsules, while the itraconazole group received six chemotherapy cycles and 400 mg oral itraconazole for five days per cycle. Results: Following completion of six chemotherapy cycles and when contrasted with the control arm, the itraconazole arm demonstrated statistically significant improvements in tumor response. The objective response rate was 80% in the itraconazole group compared with 47% in the placebo group (p = 0.015), while the disease control rate was 100% versus 80%, respectively (p = 0.023). The median progression-free survival (PFS), defined as the time point at which 50% of patients experienced disease progression or death, was 13.5 months for the overall study population. PFS was evaluated as a fixed-time endpoint at 18 months following completion of chemotherapy for the overall study population. Progression-free survival was significantly improved in the itraconazole group, with 70% of patients remaining progression-free compared with 26.7% in the placebo group (p = 0.001). Also, the itraconazole group produced significant declines in the serum levels of CA-125 (p = 0.005) and p-glycoprotein (p = 0.042) with significant elevation in VEGFR-2 (p = 0.006) as compared to the control group. Itraconazole was safe and its use was associated with a significant improvement in the quality of life (QOL). Conclusions: Itraconazole could represent a promising add-on therapy to enhance tumor response to chemotherapy in patients with ovarian cancer.
Fenofibrate attenuates doxorubicin-induced cardiotoxicity in patients with breast cancer: a randomized controlled trial
Hagar K. Dewidar, Amr A. Ghannam, Tarek M. Mostafa
Naunyn Schmiedeberg S Archives of Pharmacology, 2025
Doxorubicin-induced cardiotoxicity (DIC) is a serious condition that limits its use. Thus, this study aimed at evaluating the efficacy and safety of fenofibrate in attenuating DIC in patients with breast cancer. In this randomized controlled parallel study, 44 patients with stage II and/or stage III breast cancer were randomly allocated into two groups: group 1 (control group; n = 22) which received doxorubicin/cyclophosphamide (AC regimen) for four cycles (cycle is every 3 weeks) and group 2 (fenofibrate group; n = 22) which received AC regimen for four cycles (cycle is every 3 weeks) plus 160 mg of oral fenofibrate 24 h prior to the first cycle of chemotherapy and then once daily until the end of the four chemotherapy cycles. At baseline and after the fourth chemotherapy cycle, all participants were submitted to echocardiography (echo) to evaluate left ventricular ejection fraction (LVEF) and blood sample collection to assess the serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), myeloperoxidase (MPO), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Data was analyzed using paired and unpaired t-tests, chi-square test, and Fisher exact test. Compared to baseline, the control group (AC) produced a significant increase in the serum levels of both NT-proBNP (P = 0.004) and MPO (P < 0.001). At the end of the study and as compared to the control group, the fenofibrate group showed significantly higher LVEF (P = 0.048) and a lower incidence of cardiotoxicity (P = 0.036). Additionally, the fenofibrate group showed a significant decline in the serum levels of NT-proBNP (P < 0.001) and MPO (P < 0.001). Moreover, fenofibrate was safe and well-tolerated and did not provoke a significant elevation in liver enzymes (P > 0.05). Fenofibrate could represent a promising prophylactic therapy against doxorubicin-induced cardiotoxicity. Trial registration: ClinicalTrials.gov ID: NCT06155331. Trial registration date 1-12-2023.
Pentoxifylline as Adjuvant Therapy in Patients with Generalized Epilepsy Treated with Phenytoin: A Randomized Controlled Study
Maha A. Younis, Sahar M. El-Haggar, Wessam Mustafa, Tarek M. Mostafa
Molecular Neurobiology, 2025
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
Ahmed M. Kettana, Tarek M. Mostafa, Amr A. Ghannam, Dalia R. El-Afify
Cancer Chemotherapy and Pharmacology, 2025
Efficacy and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis: a randomized controlled study
Tarek M. Mostafa, Abeer A. El-Sayed, Abdel Moaty A. Afifi, Dalia R. El-Afify
European Journal of Clinical Pharmacology, 2025
Objective This research aimed at evaluating the effectiveness and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis (RA). Methods In this randomized controlled parallel study, 90 patients with active RA were randomized into three groups; group 1 (control group; n = 30) which received traditional therapy, group 2 (Nitazoxanide group; n = 30) which received traditional therapy plus 1 gm/day oral nitazoxanide, and group 3 (Escitalopram group; n = 30) which received traditional therapy plus 10 mg/day oral escitalopram for three months. At baseline and 3 months after treatment, clinical and functional assessments were done through the 28-joint count disease activity score using C-reactive protein (DAS28-CRP), the health assessment questionnaire-disability index (HAQ-DI), and the patient’s global assessment (PGA). Also, serum levels of high-sensitivity C-reactive protein (hs-CRP), signal transducer and activator of transcription-3 (STAT-3), Janus kinase-2 (JAK-2), toll-like receptors 4 (TLR-4), interleukin-1 beta (IL-1β), and malondialdehyde (MDA) were assessed. Data were analyzed using paired t-test and one-way analysis of variance, followed by Tukey’s HDS test. Results Three months after treatment and as compared to the control group, the nitazoxanide group showed a significant decline in PGA (P = 0.042), and serum levels of STAT-3 (P < 0.001), JAK-2 (P < 0.001), TLR-4 (P < 0.001), and IL-1β (P < 0.001). On the other hand, the escitalopram group produced a significant decrease in DAS28-CRP score (P = 0.029), HAQ-DI score (P = 0.001), and serum levels of JAK-2 (P = 0.001), TLR-4 (P < 0.001), IL-1β (P < 0.001), and MDA (P < 0.001). As compared to nitazoxanide group, the escitalopram group produced a significant decline in fatigue score (P < 0.001) and serum levels of both IL-1β (P = 0.023) and MDA (P < 0.001). Both medications were safe; however, chromaturia was the only significant nitazoxanide-related adverse effect. Conclusion Nitazoxanide and escitalopram could serve as potential adjuvant therapies for patients with RA based on their effectiveness and safety data.
Clinical study evaluating the gastroprotective effect of carvedilol in patients with ischemic heart disease on aspirin therapy
Sarah M. Elkablawy, Aliaa E. Shaban, Tarek M. Mostafa
Inflammopharmacology, 2025
Role of dexmedetomidine in brain injury: a systematic review
Rania Zekry, Rehab H. Werida, Ehab S. Hegazy, Tarek M. Mostafa
Inflammopharmacology, 2025
Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease
Mohamed E. Ramadan, Tarek M. Mostafa, Azza A. Ghali, Dalia R. El-Afify
Inflammopharmacology, 2025
Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis
Samar M. Eldadamony, Sahar M. El-Haggar, Abdel Moaty A. Ali, Tarek M. Mostafa
Inflammopharmacology, 2025
Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study
Asmaa Elsharab, Mohamed Nooh, Raghda Matard, Tarek Mostafa, Dalia El-Afify
Diabetes Metabolic Syndrome and Obesity, 2025
Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial
Khadija A.M. Glal, Sahar M. El-Haggar, Sherief M. Abdel-Salam, Tarek M. Mostafa
American Journal of Medicine, 2024
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study
Aya Ahmed El-attar, Osama Mohamed Ibrahim, Suzan Ahmed Alhassanin, Enas Said Essa, Tarek Mohamed Mostafa
European Journal of Clinical Pharmacology, 2023
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
Rehab H. Werida, Reham A. Elshafiey, Asser Ghoneim, Sherif Elzawawy, Tarek M. Mostafa
Supportive Care in Cancer, 2022
Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study
D. Abdel Hamid, Y. A. Nienaa, T. Mostafa
European Review for Medical and Pharmacological Sciences, 2022
Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer A randomized controlled clinical study
Tarek M. Mostafa, Mohamed A. Alm El-Din, Amira R. Rashdan
Saudi Medical Journal, 2022
Randomized Clinical and Biochemical Study Comparing the Effect of L-arginine and Sildenafil in Beta Thalassemia Major Children With High Tricuspid Regurgitant Jet Velocity
Eman El-Khateeb, Sahar Mohamed El-Haggar, Osama El-Razaky, Mohamed Ramadan El-Shanshory, Tarek Mohamed Mostafa
Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis
Tarek Mohamed Mostafa, Sahar Kamal Hegazy, Salwa El-morsy Abd El-Ghany, Fedaa Abd El-Monem Kotkata
European Journal of Clinical Pharmacology, 2021
Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial
Khadija A. M. Glal, Sherief M. Abd‐Elsalam, Tarek M. Mostafa
Journal of Hepato Biliary Pancreatic Sciences, 2021
The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
Mahmoud Samy Abdallah, Ahmed Hossam Eldeen, Sally Said Tantawy, Tarek Mohamed Mostafa
European Journal of Pharmacology, 2021
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes
Tarek M. Mostafa, Nashwa M. El-Gharbawy, Rehab H. Werida
Clinical Therapeutics, 2021
Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: A comparative study of Nigella sativa versus both lifestyle modification and metformin
Tarek M. Mostafa, Sahar K. Hegazy, Sherin S. Elnaidany, Walid A. Shehabeldin, Eman S. Sawan
Journal of Diabetes and Its Complications, 2021
Circulating il-6, clusterin and irisin in obese subjects with different grades of obesity: Association with insulin resistance and sexual dimorphism
Rehab H. Werida, Nashwa M. El-Gharbawy, Tarek M. Mostafa
Archives of Endocrinology and Metabolism, 2021
Antepartum and postpartum changes in adipokines, endothelial dysfunction, inflammatory markers and other biochemical parameters in preeclamptic women: A prospective observational cohort study
Amany Yasseen Talab, Haitham Aboali Hamza, Tarek Mohamed Mostafa
Journal of Applied Biomedicine, 2021
Fish oil plus wheat germ oil have no prominent effect on homocysteine levels and nutritional indices in hemodialysis patients
Hadeer Zakaria, Tarek M. Mostafa, Gamal A. El-Azab, Nagy AH Sayed-Ahmed
International Journal for Vitamin and Nutrition Research, 2021
The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
Tarek M. Mostafa, Gamal A. El-Azab, Ghada A. Atia, Noran S. Lotfy
Current Therapeutic Research Clinical and Experimental, 2021
Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study
Tarek M. Mostafa, Gamal A. El-azab, Gamal A. Badra, Alyaa S. Abdelwahed, Abeer A. Elsayed
Current Therapeutic Research Clinical and Experimental, 2021
The plausible mechanisms of tramadol for treatment of COVID-19
Nahla E. El-Ashmawy, Abdel-Halim A. Lashin, Kamal M. Okasha, Amal M. Abo Kamer, Tarek M. Mostafa, et al.
Medical Hypotheses, 2021
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease
Rehab Werida, Mahmoud Kabel, Gamal Omran, Ahmed Shokry, Tarek Mostafa
Diabetes Research and Clinical Practice, 2020
A comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity
AhmedH Elabd, TarekMohamed Mostafa, SaharKamal Hegazy, EmadM Elshebini, DaliaS Saif
Indian Journal of Medical Research, 2020
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study
Basma Mahrous El-fatatry, Osama Mohamed Ibrahim, Fatma Zakaria Hussien, Tarek Mohamed Mostafa
International Journal of Colorectal Disease, 2018
The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: A proof-of-concept, randomized, double-blind, placebo-controlled trial
Sahar Mohamed El-Haggar, Mai AbdelRaouf Eissa, Tarek Mohammed Mostafa, Khaled Sabry El-Attar, Mahmoud Samy Abdallah
Psychotherapy and Psychosomatics, 2018
Levetiracetam and lamotrigine effects as mono-and polytherapy on bone mineral density in epileptic patients
Sahar Mohamed El-Haggar, Tarek Mohamed Mostafa, Horeya Mohamed Sad Allah, Ghada Hassan Akef
Arquivos De Neuro Psiquiatria, 2018
The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial
Hadeer Zakaria, Tarek M. Mostafa, Gamal A. El-Azab, Ahmed M. Abd El Wahab, Heba Elshahawy, et al.
International Urology and Nephrology, 2017
Cardiovascular risk in Egyptian healthy consumers of different types of combined oral contraceptives pills: A comparative study
Sahar M. El-Haggar, Tarek M. Mostafa
Endocrine, 2015
Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease
Sahar Mohamed El-Haggar, Tarek Mohamed Mostafa
Hepatology International, 2015
Adipokines and biochemical changes in Egyptian obese subjects: possible variation with sex and degree of obesity
Sahar Mohamed El-Haggar, Tarek Mohamed Mostafa
Endocrine, 2015
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients
Tarek Mostafa, Gamal Badra, Mahmoud Abdallah
Turkish Journal of Gastroenterology, 2015
Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis
Gehad El-Nakib, Tarek Mostafa, Tarek Abbas, Mamdouh El-Shishtawy, Mokhtar Mabrouk, et al.
International Journal of Nephrology and Renovascular Disease, 2013
Alpha-Lipoic Acid Improves Subclinical left Ventricular Dysfunction in Asymptomatic Patients with Type 1 Diabetes
Sahar K. Hegazy, Osama A. Tolba, Tarek M. Mostafa, Manal A. Eid, Dalia R. El-Afify
Review of Diabetic Studies, 2013
Viability and functionality of bovine chromaffin cells encapsulated into alginate-PLL microcapsules with a liquefied inner core
T. Moustafa, S. Girod, F. Tortosa, R. Li, J. C. Sol, et al.
Cell Transplantation, 2006

RECENT SCHOLAR PUBLICATIONS

Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
BM Mahboub, AF Refaie, SM El-Haggar, YM Hafez, TM Mostafa
Diabetology & Metabolic Syndrome 18 (1), 17 , 2026
2026
Ketotifen for Preventing Oxaliplatin-Induced Neuropathy in Stage III Colorectal Cancer: a Randomized Controlled Trial
SS Wahby, TM Mostafa, MAA El-Din, EI Elberri
Journal of Gastrointestinal Cancer 57 (1), 106 , 2026
2026
Efficacy and safety of baclofen in the prophylaxis of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a randomized controlled trial
AG Moussa, SM El-Haggar, TM El-Mahdy, TM Mostafa
BMC Surgery , 2026
2026
L-Carnitine and Biotin as Adjunctive Therapies in Children with Moderate Persistent Asthma: A Randomized Placebo controlled Study
MO Khedr, SM El-Haggar, AM Abd El-Razik, TM Mostafa
2026
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial
KAM Glal, SM El-Haggar, SM Abdel-Salam, TM Mostafa
Scientific Reports , 2026
2026
Probiotic Supplementation as an Adjuvant Therapy in Pediatric Drug‐Resistant Epilepsy: A Double‐Blind Placebo‐Controlled Trial
AR Rashdan, SM El‐Haggar, AM Kishk, TM Mostafa
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 46 (3 … , 2026
2026
Citations: 2
Efficacy and Safety of Roflumilast in Patients with Non-Alcoholic Steatohepatitis: A Randomized Controlled Study
TM Mostafa, MS Mohamed, SM Abdel-Salam, DR El-Afify
International Journal of Pharmaceutical Sciences and Research 38 (1), 33-46 , 2026
2026
A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole—A Single-Institution Randomized Placebo-Controlled Trial
AES Besheir, SM El-Hagar, HA Tawfik, TM Mostafa
Current Oncology 33 (1), 21 , 2025
2025
Citations: 1
Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study
A Elsharab, MZ Nooh, RS Matard, TM Mostafa, DR El-Afify
Diabetes, Metabolic Syndrome and Obesity, 4193-4210 , 2025
2025
Citations: 1
Comparative clinical study to evaluate the efficacy and safety of roflumilast versus alpha-lipoic acid in type 2 diabetic patients with diabetic neuropathy
AEA Elsharab, TM Mostafa, MZ Nooh, DR El-Afify
Journal of the Neurological Sciences 480 , 2025
2025
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal cancer
AM Kettana, TM Mostafa, AA Ghannam, DR El-Afify
Cancer Chemotherapy and Pharmacology 95 (1), 72 , 2025
2025
Citations: 1
Pentoxifylline as Adjuvant Therapy in Patients with Generalized Epilepsy Treated with Phenytoin: A Randomized Controlled Study
MA Younis, SM El-Haggar, W Mustafa, TM Mostafa
Molecular Neurobiology 62 (12), 15978-15987 , 2025
2025
Efficacy and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis: a randomized controlled study
TM Mostafa, AA El-Sayed, AMA Afifi, DR El-Afify
European Journal of Clinical Pharmacology 81 (12), 1819-1832 , 2025
2025
Fenofibrate attenuates doxorubicin-induced cardiotoxicity in patients with breast cancer: a randomized controlled trial
HK Dewidar, AA Ghannam, TM Mostafa
Naunyn-Schmiedeberg's Archives of Pharmacology 398 (12), 17109-17119 , 2025
2025
Citations: 1
Clinical study evaluating the gastroprotective effect of carvedilol in patients with ischemic heart disease on aspirin therapy
SM Elkablawy, AE Shaban, TM Mostafa
Inflammopharmacology 33 (11), 6831-6838 , 2025
2025
Citations: 1
Role of dexmedetomidine in brain injury: a systematic review
R Zekry, RH Werida, ES Hegazy, TM Mostafa
Inflammopharmacology 33 (10), 5745-5756 , 2025
2025
Citations: 1
Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease
ME Ramadan, TM Mostafa, AA Ghali, DR El-Afify
Inflammopharmacology 33 (7), 3897-3908 , 2025
2025
Citations: 13
Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis
SM Eldadamony, SM El-Haggar, AMA Ali, TM Mostafa
Inflammopharmacology 33 (6), 3499-3508 , 2025
2025
Citations: 1
Allopurinol prevents cirrhosis-related complications: a quadruple blind placebo-controlled trial
KAM Glal, SM El-Haggar, SM Abdel-Salam, TM Mostafa
The American journal of medicine 137 (1), 55-64 , 2024
2024
Citations: 5
Anti-inflammatory therapy in hepatic encephalopathy: A systematic review and meta-analysis
K Glal, T Mostafa
Journal of Advanced Research 54, S4-S5 , 2023
2023

MOST CITED SCHOLAR PUBLICATIONS

The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind …
SM El-Haggar, MAR Eissa, TM Mostafa, KS El-Attar, MS Abdallah
Psychotherapy and Psychosomatics , 2018
2018
Citations: 67
Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non …
SM El-Haggar, TM Mostafa
Hepatology international 9 (3), 471-479 , 2015
2015
Citations: 67
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study
BM El-Fatatry, OM Ibrahim, FZ Hussien, TM Mostafa
International journal of colorectal disease 33 (12), 1675-1683 , 2018
2018
Citations: 61
Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes
SK Hegazy, OA Tolba, TM Mostafa, MA Eid, DR El-Afify
The review of diabetic studies: RDS 10 (1), 58 , 2013
2013
Citations: 60
Role of alpha-lipoic acid in counteracting paclitaxel-and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
RH Werida, RA Elshafiey, A Ghoneim, S Elzawawy, TM Mostafa
Supportive Care in Cancer 30 (9), 7281-7292 , 2022
2022
Citations: 48
Study on the therapeutic benefit on lactoferrin in patients with colorectal cancer receiving chemotherapy
TM Moastafa, AEDE El-Sissy, GK El-Saeed, MSED Koura
International Scholarly Research Notices 2014 (1), 184278 , 2014
2014
Citations: 48
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients
T Mostafa, G Badra, M Abdallah
Turkish Journal of Gastroenterology 26 (2), 163-169 , 2015
2015
Citations: 47
Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: A comparative study of Nigella sativa versus both lifestyle …
TM Mostafa, SK Hegazy, SS Elnaidany, WA Shehabeldin, ES Sawan
Journal of Diabetes and its Complications 35 (7), 107947 , 2021
2021
Citations: 40
Circulating IRAPe, irisin, and IL-34 in relation to insulin resistance in patients with type 2 diabetes
TM Mostafa, NM El-Gharbawy, RH Werida
Clinical therapeutics 43 (7), e230-e240 , 2021
2021
Citations: 38
The plausible mechanisms of tramadol for treatment of COVID-19
NE El-Ashmawy, AHA Lashin, KM Okasha, AMA Kamer, TM Mostafa, ...
Medical Hypotheses 146, 110468 , 2021
2021
Citations: 36
Levetiracetam and lamotrigine effects as mono-and polytherapy on bone mineral density in epileptic patients
SM El-Haggar, TM Mostafa, HMS Allah, GH Akef
Arquivos de Neuro-Psiquiatria 76 (07), 452-458 , 2018
2018
Citations: 33
Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center …
DZA Hamid, YA Nienaa, TM Mostafa
European Review for Medical & Pharmacological Sciences 26 (7) , 2022
2022
Citations: 30
Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis
GA El-Nakib, TM Mostafa, TM Abbas, MM El-Shishtawy, MM Mabrouk, ...
International journal of nephrology and renovascular disease, 161-168 , 2013
2013
Citations: 30
Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trial
KAM Glal, SM Abd‐Elsalam, TM Mostafa
Journal of Hepato‐Biliary‐Pancreatic Sciences 28 (10), 812-824 , 2021
2021
Citations: 27
Circulating IL-6, clusterin and irisin in obese subjects with different grades of obesity: association with insulin resistance and sexual dimorphism
RH Werida, NM El-Gharbawy, TM Mostafa
Archives of Endocrinology and Metabolism 65, 126-136 , 2021
2021
Citations: 27
Viability and functionality of bovine chromaffin cells encapsulated into alginate-PLL microcapsules with a liquefied inner core
T Moustafa, S Girod, F Tortosa, R Li, JC Sol, F Rodriguez, R Bastide, ...
Cell Transplantation 15 (2), 121-133 , 2006
2006
Citations: 26
The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo …
H Zakaria, TM Mostafa, GA El-Azab, AM Abd El Wahab, H Elshahawy, ...
International Urology and Nephrology 49 (10), 1851-1858 , 2017
2017
Citations: 23
Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study
TM Mostafa, MAA El-Din, AR Rashdan
Saudi Medical Journal 43 (1), 37 , 2022
2022
Citations: 22
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal …
AA El-Attar, OM Ibrahim, SA Alhassanin, ES Essa, TM Mostafa
European Journal of Clinical Pharmacology 79 (2), 299-309 , 2023
2023
Citations: 21
Adipokines and biochemical changes in Egyptian obese subjects: possible variation with sex and degree of obesity
SM El-Haggar, TM Mostafa
Endocrine 48 (3), 878-885 , 2015
2015
Citations: 19

Tarek Mostafa

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS